NEWS DETAIL

Syndax社は、再発・難治性のNPM1変異、KMT2変異、およびNUP98変異を有する急性骨髄性白血病(AML)の治療薬として、Revuforj®(レブメニブ)とデシタビン/シダザリルおよびベネトクラクスを併用した治療に関するSAVE試験のデータが『Journal of Clinical Oncology』誌に掲載されたと発表した。—GlobeNewswire

Syndax社は、再発・難治性のNPM1m、KMT2Ar、およびNUP98r AMLの治療における、Revuforj®(レブメニブ)とデシタビン/シダゾリジンおよびベネトクラクスの併用療法に関するSAVE試験のデータを、*Journal of Clinical Oncology*誌に掲載したと発表した。(GlobeNewswire)

医療情報

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Sản phẩm liên quan đến bài viết

Các sản phẩm này được tự động đối chiếu từ tiêu đề, tóm tắt và nội dung bài viết.

Câu hỏi thường gặp

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Quizartinib – Mua trực tuyến Lucius Anagrelide – Mua trực tuyến Lucius Tazemetostat – Mua trực tuyến Lucius Acalabrutinib – Mua trực tuyến.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat